If you experience persistent nausea, vomiting, or inability to tolerate food beyond the expected recovery period, seek medical advice before resuming the medication, as these symptoms may indicate ongoing gastrointestinal issues that could be exacerbated by Ozempic
Important safety considerations include a boxed warning for thyroid C-cell tumors (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2), risk of pancreatitis, gallbladder disease, and acute kidney injury with dehydration
Baseline population: 45 years old on average, 65% female, BMI 39, mean weight 113 kg, 16 years of obesity history
The single strongest predictor is the extent of the weight loss
The SURMOUNT-1 trial showed average weight loss of 20.2 percent at 72 weeks on the highest dose, a figure that stunned the medical community when it was first published